{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:32:17Z","timestamp":1792668737719,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clml.2024.03.011","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T23:16:50Z","timestamp":1712359010000},"page":"523-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4507-2396","authenticated-orcid":false,"given":"Talal El","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin H.","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Adib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Chintapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Drolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-7292","authenticated-orcid":false,"given":"Tarek","family":"Haykal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Nebhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9572-3495","authenticated-orcid":false,"given":"Arjun","family":"Mittra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0144-698X","authenticated-orcid":false,"given":"Michael","family":"Lorentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Drakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6789-4315","authenticated-orcid":false,"given":"Ankit","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dittus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Baiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Y.","family":"Chiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvari V.","family":"Yellapragada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"LaCasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clml.2024.03.011_bib0001","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era","volume":"105","author":"Gopal","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.clml.2024.03.011_bib0002","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.clml.2024.03.011_bib0003","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.03.011_bib0004","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2014-08-551598","article-title":"How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus","volume":"125","author":"Uldrick","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.03.011_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1053\/j.seminhematol.2022.11.002","article-title":"The role of viruses in HIV-associated lymphomas","volume":"59","author":"Lurain","year":"2022","journal-title":"Semin Hematol"},{"issue":"33","key":"10.1016\/j.clml.2024.03.011_bib0006","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.011_bib0007","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6334","key":"10.1016\/j.clml.2024.03.011_bib0008","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aak9510","article-title":"Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer","volume":"356","author":"Stevanovic","year":"2017","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.clml.2024.03.011_bib0009","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2024.03.011_bib0010","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.03.011_bib0011","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.03.011_bib0012","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2024.03.011_bib0013","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.03.011_bib0014","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.03.011_bib0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2024.03.011_bib0016","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.03.011_bib0017","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.011_bib0018","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: final analysis of the randomized German Hodgkin Study Group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.03.011_bib0019","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.011_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2024.03.011_bib0021","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.clml.2024.03.011_bib0022","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.03.011_bib0023","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic Hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.03.011_bib0024","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"10","key":"10.1016\/j.clml.2024.03.011_bib0025","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2024.03.011_bib0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"17","key":"10.1016\/j.clml.2024.03.011_bib0027","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.03.011_bib0028","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clml.2024.03.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002097","article-title":"Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin\u2019s lymphoma","volume":"9","author":"Lurain","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.clml.2024.03.011_bib0030","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer: a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.03.011_bib0031","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.03.011_bib0032","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium","volume":"41","author":"El Zarif","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.03.011_bib0033","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J Immunother"},{"issue":"7","key":"10.1016\/j.clml.2024.03.011_bib0034","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.03.011_bib0035","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.clml.2017.12.008","article-title":"HIV-related refractory Hodgkin lymphoma: a case report of complete response to nivolumab","volume":"18","author":"Chang","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.03.011_bib0036","unstructured":"Common Terminology Criteria for Adverse Events version 5.0. United States Department of Health and Human Services. 2020. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5\u00d77.pd. Accessed August 1, 2023."},{"issue":"27","key":"10.1016\/j.clml.2024.03.011_bib0037","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.03.011_bib0038","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.03.011_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005128","article-title":"Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer","volume":"10","author":"Odeny","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.03.011_bib0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamaoncol.2019.4648","article-title":"Immune status and associated mortality after cancer treatment among individuals with HIV in the antiretroviral therapy era","volume":"6","author":"Calkins","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2024.03.011_sbref0041","series-title":"Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV","year":"2023"},{"issue":"6","key":"10.1016\/j.clml.2024.03.011_bib0042","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/bloodadvances.2020003556","article-title":"Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma","volume":"5","author":"Merryman","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.03.011_bib0043","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"issue":"629","key":"10.1016\/j.clml.2024.03.011_bib0044","doi-asserted-by":"crossref","first-page":"eabl3836","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"issue":"17_suppl","key":"10.1016\/j.clml.2024.03.011_bib0045","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.clml.2024.03.011_bib0046","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.03.011_bib0047","doi-asserted-by":"crossref","first-page":"e2027110","DOI":"10.1001\/jamanetworkopen.2020.27110","article-title":"Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti\u2013PD1\/PDL1 clinical trials","volume":"3","author":"Reuss","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2024.03.011_bib0048","unstructured":"Cancer clinical trial eligibility criteria: patients with HIV, Hepatitis B Virus, or Hepatitis C Virus infections: Food and Drug Administration guidance for industry. 2020. Available at: https:\/\/www.fda.gov\/media\/121319\/download . Accessed August 1, 2023."}],"updated-by":[{"DOI":"10.1016\/j.clml.2024.10.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:27:48Z","timestamp":1732786068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2152265024001344"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.011","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.clml.2024.10.011","asserted-by":"object"}]},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}